Pmv Pharmaceuticals Valuation

PMVP Stock  USD 1.06  0.01  0.93%   
Today, the company appears to be undervalued. Pmv Pharmaceuticals holds a recent Real Value of $2.65 per share. The prevailing price of the company is $1.06. Our model determines the value of Pmv Pharmaceuticals from analyzing the company fundamentals such as Return On Equity of -0.52, shares outstanding of 53.21 M, and Shares Owned By Institutions of 70.62 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pmv Pharmaceuticals' valuation include:
Price Book
0.4903
Enterprise Value
-69.3 M
Enterprise Value Ebitda
1.2385
Undervalued
Today
1.06
Please note that Pmv Pharmaceuticals' price fluctuation is risky at this time. Calculation of the real value of Pmv Pharmaceuticals is based on 3 months time horizon. Increasing Pmv Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Pmv Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 1.06, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  1.06 Real  2.65 Target  7.6 Hype  1.05 Naive  1.09
The intrinsic value of Pmv Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pmv Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
2.65
Real Value
5.96
Upside
Estimating the potential upside or downside of Pmv Pharmaceuticals helps investors to forecast how Pmv stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pmv Pharmaceuticals more accurately as focusing exclusively on Pmv Pharmaceuticals' fundamentals will not take into account other important factors:
Earnings
Estimates
LowProjectedHigh
-0.41-0.36-0.23
Details
Hype
Prediction
LowEstimatedHigh
0.051.054.36
Details
Naive
Forecast
LowNext ValueHigh
0.021.094.40
Details
5 Analysts
Consensus
LowTarget PriceHigh
6.927.608.44
Details
Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pmv Pharmaceuticals' intrinsic value based on its ongoing forecasts of Pmv Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pmv Pharmaceuticals' closest peers.

Pmv Pharmaceuticals Cash

34.95 Million

Pmv Pharmaceuticals Total Value Analysis

Pmv Pharmaceuticals is at this time anticipated to have valuation of (69.25 M) with market capitalization of 56.94 M, debt of 1.19 M, and cash on hands of 277.43 M. The negative valuation of Pmv Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Pmv Pharmaceuticals fundamentals.
  Takeover PriceMarket CapDebt ObligationsCash
(69.25 M)
56.94 M
1.19 M
277.43 M

Pmv Pharmaceuticals Asset Utilization

One of the ways to look at asset utilization of Pmv is to check how much profit was generated for every dollar of assets it reports. Pmv Pharmaceuticals holds a negative application of assets of -0.32 pct., losing $0.003202 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Pmv Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.
 
Covid
 
Interest Hikes

Pmv Pharmaceuticals Profitability Analysis

Based on Pmv Pharmaceuticals' profitability indicators, Pmv Pharmaceuticals may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Pmv Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2019-03-31
Previous Quarter
-21.2 M
Current Value
-21.1 M
Quarterly Volatility
5.9 M
 
Covid
 
Interest Hikes
As of 02/20/2026, Gross Profit is likely to drop to about (1.1 M)
For Pmv Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Pmv Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Pmv Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Pmv Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Pmv Pharmaceuticals over time as well as its relative position and ranking within its peers.

Pmv Pharmaceuticals Earnings per Share Projection vs Actual

By analyzing Pmv Pharmaceuticals' earnings estimates, investors can diagnose different trends across Pmv Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Pmv Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
Pmv Pharmaceuticals is projected to generate -0.358125 in earnings per share on the 31st of December 2026. Pmv Pharmaceuticals earnings estimates show analyst consensus about projected Pmv Pharmaceuticals EPS (Earning Per Share). It derives the highest and the lowest estimates based on Pmv Pharmaceuticals' historical volatility. Many public companies, such as Pmv Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm.

Pmv Pharmaceuticals Ownership Allocation

Pmv Pharmaceuticals owns a total of 53.21 Million outstanding shares. The majority of Pmv Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Pmv Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Pmv Pharmaceuticals. Please pay attention to any change in the institutional holdings of Pmv Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Pmv Pharmaceuticals Profitability Analysis

Net Loss for the year was (58.71 M) with profit before overhead, payroll, taxes, and interest of 0.

About Pmv Pharmaceuticals Valuation

The stock valuation mechanism determines Pmv Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pmv Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pmv Pharmaceuticals. We calculate exposure to Pmv Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pmv Pharmaceuticals's related companies.
Last ReportedProjected for Next Year
Gross Profit-1 M-1.1 M

Pmv Pharmaceuticals Current Valuation Indicators

Pmv Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Pmv Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pmv Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pmv Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pmv Pharmaceuticals' worth.

Additional Tools for Pmv Stock Analysis

When running Pmv Pharmaceuticals' price analysis, check to measure Pmv Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pmv Pharmaceuticals is operating at the current time. Most of Pmv Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pmv Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pmv Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pmv Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.